ConductScience.org, home

Paper40969762

Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling.

Andreou T and 4 others. Front Immunol, 2025. Cited by 25 papers, by iCite.

Cite this record

ConductScience Library. Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. Papers, record 40969762. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40969762

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling.
PubMed
Journal
Front Immunol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
25
iCite
Relative citation ratio, by iCite
6.13, provisional
iCite
Revised in PubMed
2025-09-21
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Andreou TTereza
2Neophytou CConstantina
3Kalli MMaria
4Mpekris FFotios
5Stylianopoulos TTriantafyllos

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Tumor MicroenvironmentMajor topic
NeoplasmsMajor topic
Immunotherapy, AdoptiveMajor topic
Receptors, Chimeric AntigenMajor topic
T-LymphocytesMajor topic
Humans
Animals

Source PubMed

Download CSV of topics

References171

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129641319Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.Hum Gene Ther2018https://conductscience.org/library/papers/29641319PubMed
225800760Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.J Clin Oncol2015https://conductscience.org/library/papers/25800760PubMed
329508855Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Nat Rev Clin Oncol2018https://conductscience.org/library/papers/29508855PubMed
429443960TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.Nature2018https://conductscience.org/library/papers/29443960PubMed
517255361Inhibitory effect of tumor cell-derived lactic acid on human T cells.Blood2007https://conductscience.org/library/papers/17255361PubMed
635769460NK Cells Under Hypoxia: The Two Faces of Vascularization in Tumor and Pregnancy.Front Immunol2022https://conductscience.org/library/papers/35769460PubMed
729385370Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med2018https://conductscience.org/library/papers/29385370PubMed
834175021
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet2021https://conductscience.org/library/papers/34175021PubMed
935793612Scale-out production of extracellular vesicles derived from natural killer cells via mechanical stimulation in a seesaw-motion bioreactor for cancer therapy.Biofabrication2022https://conductscience.org/library/papers/35793612PubMed
1017606728Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.Clin Cancer Res2007https://conductscience.org/library/papers/17606728PubMed
1112427307Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.Hum Gene Ther2002https://conductscience.org/library/papers/12427307PubMed
1236110930Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.Front Oncol2022https://conductscience.org/library/papers/36110930PubMed
1339475618Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments.Sci Adv2024https://conductscience.org/library/papers/39475618PubMed
1439240078Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.Cancer Res Commun2024https://conductscience.org/library/papers/39240078PubMed
1524876563Current concepts in the diagnosis and management of cytokine release syndrome.Blood2014https://conductscience.org/library/papers/24876563PubMed
1631959281T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity.Elife2020https://conductscience.org/library/papers/31959281PubMed
1732758419Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy.Immunity2020https://conductscience.org/library/papers/32758419PubMed
1817108138CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.Cancer Res2006https://conductscience.org/library/papers/17108138PubMed
1921478334Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β.Clin Cancer Res2011https://conductscience.org/library/papers/21478334PubMed
2024167277Combining two strategies to improve perfusion and drug delivery in solid tumors.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/24167277PubMed

See all 171 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.

PMIDTitleJournalYearIn PapersSource
42765849IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells.Cancer Immunol Res2026https://conductscience.org/library/papers/42765849PubMed
42700448CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.Rev Med Virol2026https://conductscience.org/library/papers/42700448PubMed
42630674Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers.Oncol Res2026https://conductscience.org/library/papers/42630674PubMed
42509832Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities.Biomolecules2026https://conductscience.org/library/papers/42509832PubMed
42454036Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology.Front Immunol2026https://conductscience.org/library/papers/42454036PubMed
42400102Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomark Res2026https://conductscience.org/library/papers/42400102PubMed
42316257Cellular immunotherapy in melanoma: the next frontier in cancer treatment.J Exp Clin Cancer Res2026https://conductscience.org/library/papers/42316257PubMed
42183245Supercharging the metabolic engine: mitochondrial engineering strategies for CAR-T persistence in solid tumors.Front Immunol2026https://conductscience.org/library/papers/42183245PubMed
42183218Decoding the spatiotemporal dynamics of tumor immune niche remodeling in cancer immunotherapy.Front Immunol2026https://conductscience.org/library/papers/42183218PubMed
42064077PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer: a next-generation engineering perspective on stem cell-derived immune effectors.Front Immunol2026https://conductscience.org/library/papers/42064077PubMed
41997128Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature.Cell2026https://conductscience.org/library/papers/41997128PubMed
41993194CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead.Front Immunol2026https://conductscience.org/library/papers/41993194PubMed
41944897CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.Mol Biol Rep2026https://conductscience.org/library/papers/41944897PubMed
41865195Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies.Clin Transl Oncol2026https://conductscience.org/library/papers/41865195PubMed
41859142Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies.Front Med (Lausanne)2026https://conductscience.org/library/papers/41859142PubMed
41751878In Vivo CAR-T Therapies-A New Era of Programmable Immunity.Int J Mol Sci2026https://conductscience.org/library/papers/41751878PubMed
41737839Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors.Small Sci2026https://conductscience.org/library/papers/41737839PubMed
41488642CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.Front Immunol2025https://conductscience.org/library/papers/41488642PubMed
41303538Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.Int J Mol Sci2025https://conductscience.org/library/papers/41303538PubMed
41303327Special Issue "Molecular Advances in Cancer Immunotherapy".Int J Mol Sci2025https://conductscience.org/library/papers/41303327PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40969762

GET https://conductscience.org/api/papers/v1/40969762/references?page=2